Serious fungal infections cause 1.3 million deaths annually worldwide.
Researchers have identified a new class of antifungals to treat the more than 300 million people worldwide who develop serious fungal infections
The research is described in the current issue of mBio, the online open-access journal of the American Society for Microbiology.
“Fungal infections are a significant cause of morbidity and mortality worldwide and current antifungal drugs have drawbacks. These new drugs may pave the way for the development of a new class of antifungals,” said principal investigator Maurizio Del Poeta, MD, a professor in the Department of Molecular Genetics and Microbiology at Stony Brook University, Stony Brook, New York.
Fungal infections are most commonly found in individuals with medical conditions that compromise the immune system, such as AIDS, or individuals who are being treated with immunosuppressives, such as those battling cancer. The three classes of antifungal drugs currently available—azoles, polyenes, and echinocandins—are far from optimal.
“Even with treatment, the mortality rate of invasive fungal infections is over 50%,” said Dr. Del Poeta. “The drugs don’t work that well. They are toxic, so they affect other organs, and they are static, meaning they may be able to stop a fungus from replicating but they are not able to kill the fungus.” Current antifungals also have a narrow spectrum of activity, and some interact with other drugs such as chemotherapy agents and immunosuppressants.”
Previous research has shown that when fungal cells lack a lipid called glucosylceramide (GlcCer), they are unable to replicate. Seeking to exploit this weakness and develop a new class of antifungals, an international group of researchers screened a synthetic drug library for compounds that target the synthesis of fungal but not mammalian GlcCer. “The enzymes that are important for the synthesis of fungal glucosylceramide are different than the ones important for the synthesis of mammalian glucosylceramide,” said Dr. Del Poeta. “We thought that because the pathway is totally different, we could specifically target the fungal glucosylceramide without affecting mammalian glucosylceramide, and that is exactly what we did.”
They identified two compounds, BHBM and its derivative DO, that decreased levels of fungal but not mammalian glucosylceramide. In test tube and animal studies, these compounds were highly effective against several pathogenic fungi and were well tolerated in animals. The drugs were effective when used alone or in combination with other classes of antifungals. The researchers plan to spend the next five years fine-tuning their research and identifying even more effective compounds that inhibit fungal glucosylceramide.
Serious fungal infections cause 1.3 million deaths annually worldwide. The most common and life-threatening fungal infections are cryptococcosis, candidiasis, aspergillosis, and pneumocystosis.
Read more: Researchers Identify New Class of Antifungal Agents
The Latest on: Antifungals
[google_news title=”” keyword=”Antifungals” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antifungals
- Global Ringworm Treatment Industryon April 30, 2024 at 5:42 am
Global Ringworm Treatment Industry is projected to grow from US$ 8.38 Bn in 2023 to US$ 13.91 Bn by 2033, at a CAGR of 5.2% ...
- The Best Probiotics for Menon April 29, 2024 at 1:22 pm
Branded content. Us Weekly has affiliate partnerships so we may receive compensation for some links to products and services. As I venture toward a healthier lifestyle, probiotics have been something ...
- Explained | What is antimicrobial resistance?on April 29, 2024 at 11:45 am
New evidence from the World Health Organisation (WHO) shows the extensive overuse of antibiotics during COVID-19 pandemic worldwide, which may have exacerbated the silent spread of antimicrobial ...
- CDTX Cidara Therapeutics, Inc.on April 29, 2024 at 9:10 am
The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia ...
- Combination Antifungal Therapy for Invasive Fungal Infections in Children and Adultson April 28, 2024 at 5:00 pm
[87] Nikkomycin Z, a chitin synthase inhibitor, has been evaluated with various combinations of other antifungals and demonstrated synergy with caspofungin and micafungin. [91] A very recent ...
- Antimicrobial resistance projected to kill 10 million people each yearon April 28, 2024 at 10:45 am
Dr. James Gill addresses antimicrobial resistance and its accelerating crisis, emphasizing the need for patient education.
- I’m 24 & going on a lads’ holiday but think I’m allergic to condoms, please help! Dr Jeff answers your health questionson April 27, 2024 at 12:22 pm
DR Jeff Foster is The Sun on Sunday’s resident doctor and is here to help YOU. Dr Jeff, 43, splits his time between working as a GP in Leamington Spa, Warks, and running his clinic, H3 ...
- Superbugs could lower your life expectancy by nearly 2 years, report says. What to know about antimicrobial resistanceon April 25, 2024 at 5:25 pm
Public Health Emergency, a group of international political, public health, and biomedical leaders warns of another menace to human life that could also trigger economic loss. Antimicrobial ...
- Allergy to Imidazole Antifungals Retained in Shoeson April 19, 2024 at 4:59 pm
Topical imidazole antifungals are commonly used as first-line over-the-counter treatment of foot dermatoses. Patients may not provide a history of using these agents, but such agents can persist ...
- Unruly Gut Fungi Can Make Your Covid Worseon April 19, 2024 at 4:01 am
An infection can upset your microbiome, and if certain gut fungi run riot, this can kick the immune system into overdrive.
via Bing News